It has been reported that the metabolic features determined sensitivity to the PI3K/mTOR dual inhibitor gedatolisib in small cell lung cancer cells.41 We also found that CYH33 moderately inhibited the proliferation of ESCC cells without inducing cell cycle arrest, suggesting that CYH33 exerted its activity via both cell cycle-dependent and -independent manners. This evidence concerns the gene MTOR and small cell lung carcinoma.